United States-based Neurocrine Biosciences has signed a research collaboration with United States-based Jnana Therapeutics.

It was reported yesterday that the collaboration is aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system disorders. It will leverage Jnana Therapeutics' proprietary drug discovery platform across the solute carrier family of transporters and Neurocrine's research and development expertise in central nervous system disorders to advance new medicines.

According to the terms of the contract, both firms will work jointly to identify novel compounds, after which time Neurocrine will be responsible for further lead optimisation, and the development and commercialisation of any potential therapies arising from the collaboration.